Avacta establishes new Therapeutics HQ at Scale Space science cluster in London
Avacta Group, a clinical stage oncology drug company developing cancer therapies and diagnostics based on its proprietary pre|CISION and Affimer platforms, has relocated its Therapeutics division to a new headquarters at Scale Space, in Imperial College’s White City Campus, London.
The new headquarters, which will see Avacta be part of a life science cluster at the west London site, brings together its research and development teams to support the continued growth of the company’s pre-clinical and clinical development pipelines of cancer therapies. The move follows the transition of AVA6000, the company’s lead pre|CISION targeted chemotherapy programme and a tumour activated form of doxorubicin, into the clinic in August 2021.
Opened in July 2020 as a joint venture between Blenheim Chalcot, the UK’s leading digital venture builder, and Imperial College London, Scale Space is part of the broader White City Innovation District. White City is currently home to more than 140 companies across a broad range of industries including pharmaceutical and biotech.
Dr Fiona McLaughlin, Chief Scientific Officer of Avacta, commented: “This move is the result of a clear vision to bring together the research and development teams into one hub to facilitate the translation of our in-house research from bench to bedside. We are now at the heart of the innovative White City community in London, readily accessible to our collaborators around the world and poised to take Avacta to the next level in its evolution as a clinical stage biopharmaceutical company.”